◎ Sugi Atlas

Atlas / Drug / Carboplatin

Carboplatin

drug
On this page

Also known as CarboplatineCarboplatinoCarboplatinumJM-8NSC-201345NSC-241240Paraplatincis-Diamineplatinum (II) ComplexPt(II) ComplexPlatinum complexPlatinum (II) complexCis-Platinum (II) ConjugateSID26748613SID50112939SID26748614SID26748615SID50110983SID568180SID144206139

Summary

Carboplatin (CHEMBL1351) is an approved small molecule (ATC L01XA02); indicated across 196 conditions including ovarian carcinoma and neoplasm; with CIViC clinical evidence for 34 variant-indication associations (e.g. EGFR L858R OR EGFR Exon 19 Deletion in lung non-small cell carcinoma).

At a glance

  • Status: Approved (max clinical phase 4)
  • Modality: Small molecule
  • ATC class: L01XA02
  • Indications: 196 conditions
  • Clinical trials: 2,753
  • Precision-oncology evidence (CIViC): 34 variant–indication associations

Identifiers

Drug identity and classification

FieldValue
ChEMBL IDCHEMBL1351
NameCarboplatin
TypeSmall molecule
Max phase4
ATCL01XA02

Also known as: Carboplatin, Carboplatine, Carboplatino, Carboplatinum, JM-8, NSC-201345, NSC-241240, Paraplatin, cis-Diamineplatinum (II) Complex, carboplatin, Pt(II) Complex, Platinum complex

Targets

Targets

Broader ChEMBL bioactivity targets: 14 (assay-derived). Sample: Tyrosyl-DNA phosphodiesterase 1, Microtubule-associated protein tau, Lysine-specific demethylase 4E, Fructose-bisphosphate aldolase, 4’-phosphopantetheinyl transferase ffp, Ferritin light chain, 15-hydroxyprostaglandin dehydrogenase [NAD(+)], Histone-lysine N-methyltransferase 2A, Menin/Histone-lysine N-methyltransferase MLL, Polyunsaturated fatty acid lipoxygenase ALOX15.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 19 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

TargetpChemblTypeValueUnitActivity ID
ALOX156.4Potency398.1nMCHEMBL_ACT_4469704
MAPT5.5Potency3162nMCHEMBL_ACT_4530851
MAPT5.35Potency4467nMCHEMBL_ACT_4054080
Q9F4F75.2Potency6310nMCHEMBL_ACT_4363150

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

196 indications (6 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

IndicationTrial phaseMONDOEFO
ovarian carcinoma4MONDO:0005140EFO:0001075
neoplasm4MONDO:0005070EFO:0000616
ovarian neoplasm4MONDO:0021068EFO:0003893
ovarian cancer4MONDO:0008170MONDO:0008170
ependymoma3MONDO:0016698EFO:1000028
breast carcinoma3MONDO:0004989EFO:0000305
non-small cell lung carcinoma3MONDO:0005233EFO:0003060
cervical carcinoma3MONDO:0005131EFO:0001061
glioblastoma3MONDO:0018177EFO:0000519
neoplasm of mature B-cells3MONDO:0004949EFO:0000096
head and neck squamous cell carcinoma3MONDO:0010150EFO:0000181
hepatocellular carcinoma3MONDO:0007256EFO:0000182
Hodgkins lymphoma3MONDO:0004952EFO:0000183
carcinoma3MONDO:0004993EFO:0000313
cutaneous melanoma3MONDO:0005012EFO:0000389
diffuse large B-cell lymphoma3MONDO:0018905EFO:0000403
germ cell tumor3MONDO:0005040EFO:0000514
lymphoma3MONDO:0005062EFO:0000574
mesothelioma3MONDO:0005065EFO:0000588
neuroblastoma3MONDO:0005072EFO:0000621
thyroid gland papillary carcinoma3MONDO:0005075EFO:0000641
sarcoma3MONDO:0005089EFO:0000691
small cell lung carcinoma3MONDO:0008433EFO:0000702
squamous cell carcinoma3MONDO:0005096EFO:0000707
squamous cell lung carcinoma3MONDO:0005097EFO:0000708
melanoma3MONDO:0005105EFO:0000756
malignant pleural mesothelioma3MONDO:0005112EFO:0000770
cervical adenocarcinoma3MONDO:0005153EFO:0001416
anaplastic astrocytoma3MONDO:0016684EFO:0002499
metastatic melanoma3MONDO:0005191EFO:0002617
carcinoma of esophagus3MONDO:0019086EFO:0002916
medulloblastoma3MONDO:0007959EFO:0002939
lung large cell carcinoma3MONDO:0003050EFO:0003050
brain neoplasm3MONDO:0021211EFO:0003833
tumor of uterus3MONDO:0021353EFO:0003859
breast neoplasm3MONDO:0021100EFO:0003869
endometrium neoplasm3MONDO:0021251EFO:0004230
testicular cancer3MONDO:0005447EFO:0004281
upper aerodigestive tract neoplasm3MONDO:0005398EFO:0004284
primitive neuroectodermal tumor3MONDO:0005462EFO:0005235
triple-negative breast carcinoma3MONDO:0005494EFO:0005537
esophageal squamous cell carcinoma3MONDO:0005580EFO:0005922
non-Hodgkin lymphoma3MONDO:0018908EFO:0005952
head and neck cancer3MONDO:0005627EFO:0006859
fallopian tube carcinoma3MONDO:0006206EFO:1000251
inflammatory breast carcinoma3MONDO:0006804EFO:1000984
peritoneal neoplasm3MONDO:0006901EFO:1001100
female reproductive organ cancer3MONDO:0001416EFO:1001331
endometrial carcinoma3MONDO:0002447EFO:1001512
intrahepatic cholangiocarcinoma3MONDO:0003210EFO:1001961
soft tissue sarcoma3MONDO:0018078EFO:1001968
lung adenocarcinoma3MONDO:0005061EFO:0000571
undifferentiated carcinoma3MONDO:0005617EFO:0006772
urothelial carcinoma3MONDO:0040679EFO:0008528
uterine carcinosarcoma3MONDO:0006485EFO:1000613
oropharynx cancer3MONDO:0004608EFO:1001931
astrocytoma (excluding glioblastoma)3MONDO:0019781EFO:0000272
ganglioneuroblastoma3MONDO:0005035EFO:0000502
peripheral neuropathy3MONDO:0005244EFO:0003100
peripheral nervous system disorder3MONDO:0003620EFO:0004149
central nervous system neoplasm3MONDO:0006130EFO:1000158
hepatoblastoma3MONDO:0018666EFO:1000292
brain cancer3MONDO:0001657MONDO:0001657
fallopian tube neoplasm3MONDO:0021092MONDO:0002158
laryngeal neoplasm3MONDO:0021071MONDO:0002358
kidney cancer3MONDO:0002367MONDO:0002367
uterine cancer3MONDO:0002715MONDO:0002715
skin neoplasm3MONDO:0002531MONDO:0002898
seminoma3MONDO:0003001MONDO:0003001
lung neoplasm3MONDO:0021117MONDO:0008903
follicular lymphoma3MONDO:0018906MONDO:0018906
oral cavity squamous cell carcinoma3MONDO:0004958EFO:0000199
oral cavity neoplasm3MONDO:0021245EFO:0003868
anemia3MONDO:0002280EFO:0004272
head and neck neoplasm3MONDO:0005586EFO:0005950
laryngeal squamous cell carcinoma3MONDO:0005595EFO:0006352
glioma3MONDO:0021042MONDO:0100342
cholangiocarcinoma3MONDO:0019087EFO:0005221
malignant peritoneal mesothelioma3MONDO:0005512EFO:0005567
retinoblastoma3MONDO:0008380MONDO:0008380
uterine corpus cancer3MONDO:0006003EFO:0007532
urethra neoplasm3MONDO:0021239EFO:0003846
paraganglioma3MONDO:0000448EFO:1000453
colorectal neoplasm3MONDO:0005335MONDO:0005575
nasopharyngeal carcinoma3MONDO:0015459MONDO:0015459
prostate adenocarcinoma2MONDO:0005082EFO:0000673
prostate carcinoma2MONDO:0005159EFO:0001663
metastatic prostate carcinoma2MONDO:0004956EFO:0000196
myelodysplastic syndrome2MONDO:0018881EFO:0000198
acute myeloid leukemia2MONDO:0018874EFO:0000222
adenocarcinoma2MONDO:0004970EFO:0000228
minimally invasive lung adenocarcinoma2MONDO:0004991EFO:0000308
Burkitt lymphoma2MONDO:0007243EFO:0000309
ductal breast carcinoma in situ2MONDO:0005023EFO:0000432
leiomyosarcoma2MONDO:0005058EFO:0000564
leukemia2MONDO:0005059EFO:0000565
oligoastrocytoma2MONDO:0016702EFO:0000630
osteosarcoma2MONDO:0009807EFO:0000637
anaplastic oligodendroglioma2MONDO:0016696EFO:0002501
exocrine pancreatic carcinoma2MONDO:0005192EFO:0002618
nasopharyngeal neoplasm2MONDO:0005375EFO:0004252
male breast carcinoma2MONDO:0005628EFO:0006861
gliosarcoma2MONDO:0016681EFO:1001465
cutaneous neuroendocrine carcinoma2MONDO:0019210EFO:1001471
brainstem neoplasm2MONDO:0021228EFO:1001767
hereditary breast ovarian cancer syndrome2MONDO:0003582Orphanet:145
endometrioid adenocarcinoma2MONDO:0005026EFO:0000466
carcinoid tumor2MONDO:0005369EFO:0004243
thymic carcinoma2MONDO:0006451EFO:1000576
thymoma2MONDO:0006456EFO:1000581
myeloproliferative neoplasm2MONDO:0020076EFO:0002428
pancreatic endocrine carcinoma2MONDO:0005893EFO:0007416
ovarian serous cystadenocarcinoma2MONDO:0006046EFO:1000043
thrombotic disease2MONDO:0000831MONDO:0000831
gastric neoplasm2MONDO:0021085MONDO:0001056
vulva cancer2MONDO:0001528MONDO:0001528
neuroendocrine carcinoma2MONDO:0002120MONDO:0002120
carcinosarcoma2MONDO:0002928MONDO:0002928
salivary gland cancer2MONDO:0004669MONDO:0004669
gallbladder neoplasm2MONDO:0021253MONDO:0005411
ureter cancer2MONDO:0008627MONDO:0008627
Wilms tumor2MONDO:0006058MONDO:0019004
gallbladder carcinoma2MONDO:0003220EFO:1001956
gastrointestinal stromal tumor2MONDO:0011719MONDO:0011719
mixed neoplasm2MONDO:0021043MONDO:0021043
B-cell non-Hodgkin lymphoma2MONDO:0015759EFO:1001938
vulvar carcinoma2MONDO:0005215EFO:0002921
bone neoplasm2MONDO:0019060EFO:0003820
pancreatic neoplasm2MONDO:0021040EFO:0003860
bone cancer2MONDO:0002129EFO:1000350
malignant mesothelioma2MONDO:0006292EFO:1000355
retina neoplasm2MONDO:0021231EFO:1000509
bile duct neoplasm2MONDO:0021662MONDO:0003059
thyroid gland follicular carcinoma1MONDO:0005034EFO:0000501
pancreatic insulin-producing neuroendocrine tumor1MONDO:0005048EFO:0000549
HIV infectious disease1MONDO:0005109EFO:0000764
plasma cell myeloma1MONDO:0009693EFO:0001378
anaplastic large cell lymphoma1MONDO:0020325EFO:0003032
verrucous carcinoma1MONDO:0006006EFO:0007535
somatostatinoma1MONDO:0006976EFO:1001187
mantle cell lymphoma1MONDO:0018876EFO:1001469
adrenal cortex carcinoma1MONDO:0006639EFO:1000796
hypopharyngeal carcinoma1MONDO:0005216EFO:0002938
pericardial effusion1MONDO:0001370MONDO:0001370
vaginal cancer1MONDO:0001402MONDO:0001402
anus neoplasm1MONDO:0003046MONDO:0001879
appendiceal neoplasm1MONDO:0001236MONDO:0003196
renal cell carcinoma1MONDO:0005086EFO:0000681
skin disorder1MONDO:0005093EFO:0000701
plasma cell neoplasm1MONDO:0004959EFO:0000200
neuroendocrine neoplasm1MONDO:0019496EFO:1001901
cystic, mucinous, and serous neoplasm1MONDO:0006720MONDO:0037256

44 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2,753.

Phase distribution

(phase/status distribution below is over 1,600 sampled trials of the 2,753 total).

PhaseTrials
PHASE2792
PHASE3567
PHASE1/PHASE2166
PHASE2/PHASE353
PHASE422

Top trials by phase / activity

NCTPhaseStatusTitle
NCT05420454PHASE4RECRUITINGA Study for the Neoadjuvant Treatment of Breast Cancer
NCT05420467PHASE4RECRUITINGA Study for the Adjuvant Treatment of Breast Cancer
NCT05689671PHASE4ACTIVE_NOT_RECRUITINGPemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
NCT05843292PHASE4NOT_YET_RECRUITINGShort-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer
NCT06457503PHASE4RECRUITINGA Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer
NCT06485739PHASE4NOT_YET_RECRUITINGIrinotecan Liposomes for the Treatment of Neuroendocrine Carcinoma
NCT07093931PHASE4NOT_YET_RECRUITINGEfficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
NCT01020786PHASE4COMPLETEDA Study in Non-squamous Non Small Cell Lung Cancer in Asian Patients
NCT01317615PHASE4COMPLETEDRAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation
NCT01424839PHASE4UNKNOWNProspective Trial for the Diagnosis and Treatment of Intracranial Germ Cell Tumors
NCT01706120PHASE4UNKNOWNStudy of Clinical and Biological Prognostic Factors in Patients With Ovarian Cancer Receiving Carboplatin +Paclitaxel With Bevacizumab
NCT02035345PHASE4TERMINATEDSlowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment
NCT02103244PHASE4UNKNOWNValidation of an Adjusted Dosing Algorithm of Carboplatin
NCT02151149PHASE4COMPLETEDSafety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly
NCT02207361PHASE4UNKNOWNPaclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer
NCT02299765PHASE4TERMINATEDIntercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC
NCT02419742PHASE4COMPLETEDSafety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen
NCT03092986PHASE4COMPLETEDOutcome of Cisplatin and Vinblastine Versus Paclitaxel and Carboplatin as Sequential Chemotherapy Followed by Radiotherapy in Locally Advanced Non-small Cell Lung Cancer
NCT03794778PHASE4UNKNOWNEvaluation of PLD Combined With Carboplatin Versus Paclitaxel Plus Carboplatin in the First-line Treatment of Epithelial Ovarian Cancer
NCT03799601PHASE4UNKNOWNDocetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC
NCT04489888PHASE4COMPLETEDA Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)
NCT05730777PHASE4UNKNOWNCorrelation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics
NCT00392327PHASE3ACTIVE_NOT_RECRUITINGChemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
NCT00565851PHASE3ACTIVE_NOT_RECRUITINGCarboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
NCT00588770PHASE3ACTIVE_NOT_RECRUITINGChemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
NCT01057069PHASE2/PHASE3ACTIVE_NOT_RECRUITINGNeo Adjuvant Chemotherapy in Triple Negative Breast Cancer
NCT01081262PHASE3ACTIVE_NOT_RECRUITINGCarboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer
NCT01167712PHASE3ACTIVE_NOT_RECRUITINGPaclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT01566240PHASE3ACTIVE_NOT_RECRUITINGInduction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer
NCT01646034PHASE3ACTIVE_NOT_RECRUITINGHigh Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer
NCT01704716PHASE3RECRUITINGHigh Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
NCT01706939PHASE3ACTIVE_NOT_RECRUITINGThe Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer
NCT02176967PHASE3ACTIVE_NOT_RECRUITINGResponse and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma
NCT02341989PHASE3ACTIVE_NOT_RECRUITINGAdjuvant Bleomycin, Etoposide and Cisplatin (BEP) Versus Carboplatin in Stage I Seminomatous Testicular Cancer
NCT02375204PHASE3ACTIVE_NOT_RECRUITINGStandard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
NCT02429687PHASE3RECRUITINGTC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
NCT02429700PHASE3RECRUITINGTC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
NCT02445391PHASE3ACTIVE_NOT_RECRUITINGPlatinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
NCT02446600PHASE3ACTIVE_NOT_RECRUITINGTesting the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT02453282PHASE3ACTIVE_NOT_RECRUITINGPhase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Clinical evidence (CIViC)

Variant × indication × effect (34 predictive associations from 34 curated evidence items):

VariantIndicationEffectTherapyLevelCIViC
EGFR L858R OR EGFR Exon 19 DeletionLung Non-small Cell CarcinomaSensitivity/ResponseCarboplatin + Pemetrexed + AmivantamabCIViC AEID12156
ABCB1 I1145ILung Non-small Cell CarcinomaSensitivity/ResponseCisplatin + CarboplatinCIViC BEID675
BRCA1 MutationTriple-receptor Negative Breast CancerSensitivity/ResponseCisplatin + CarboplatinCIViC BEID1684
BRCA2 MutationTriple-receptor Negative Breast CancerSensitivity/ResponseCarboplatin + CisplatinCIViC BEID1685
CCND1 AmplificationSkin MelanomaSensitivity/ResponseSorafenib + Carboplatin + PaclitaxelCIViC BEID1495
CDK2 CYTOPLASMIC EXPRESSIONTriple-receptor Negative Breast CancerSensitivity/ResponseEribulin + CarboplatinCIViC BEID2969
EMSY OverexpressionOvarian Serous CarcinomaSensitivity/ResponsePaclitaxel + Bevacizumab + CarboplatinCIViC BEID12149
ERBB2 OverexpressionEndometrial Serous AdenocarcinomaSensitivity/ResponseCarboplatin + Paclitaxel + TrastuzumabCIViC BEID7386
ERCC1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseGemcitabine + CarboplatinCIViC BEID10142
ERCC2 K751QLung Non-small Cell CarcinomaSensitivity/ResponsePaclitaxel + CarboplatinCIViC BEID677
KRAS AmplificationSkin MelanomaSensitivity/ResponseSorafenib + Docetaxel + CarboplatinCIViC BEID1497
MSI HighEndometrial CancerSensitivity/ResponseCarboplatin + Dostarlimab + PaclitaxelCIViC BEID12341
MSI HighEndometrial CancerSensitivity/ResponsePaclitaxel + Dostarlimab + CarboplatinCIViC BEID12343
PTEN LossSolid TumorSensitivity/ResponseBuparlisib + Carboplatin + PaclitaxelCIViC BEID5957
RAF1 AmplificationSkin MelanomaSensitivity/ResponsePaclitaxel + Sorafenib + CarboplatinCIViC BEID1496
RRM1 UnderexpressionLung Non-small Cell CarcinomaSensitivity/ResponseCarboplatin + GemcitabineCIViC BEID10143
TOP1 EXPRESSIONOvarian CancerSensitivity/ResponseCarboplatin + Cyclophosphamide + TopotecanCIViC BEID910
XRCC1 Q399RCervical CancerSensitivity/ResponseCisplatin + CarboplatinCIViC BEID673
KRAS RS61764370Epithelial Ovarian CancerResistancePaclitaxel + CarboplatinCIViC BEID664
TP53 ALTERATIONOvarian CancerResistanceCarboplatin + CisplatinCIViC BEID2771
TP53 OverexpressionOvarian CancerResistanceCarboplatin + CisplatinCIViC BEID3013
EGFR::SEPTIN14 FusionLung AdenocarcinomaSensitivity/ResponseCarboplatin + Paclitaxel Liposome + IcotinibCIViC CEID10914
MET Exon 14 Skipping Mutation AND CD274 OverexpressionLung AdenocarcinomaSensitivity/ResponseCarboplatin + PemetrexedCIViC CEID11397
NF1 Splice Site (c.205-1G>C) AND NF1 G629RPilocytic AstrocytomaSensitivity/ResponseVincristine + Carboplatin + Trametinib + SelumetinibCIViC CEID12271
PTEN LossCancerSensitivity/ResponseCarboplatin + Buparlisib + PaclitaxelCIViC CEID714
NF2 Y177fsPeritoneal MesotheliomaResistanceCarboplatin + CisplatinCIViC CEID649
TP53 R273LOvarian CancerResistanceCarboplatin + CisplatinCIViC CEID2286
TP53 Y234COvarian CancerResistanceCarboplatin + CisplatinCIViC CEID2745
GSTP1 DeletionOvarian CarcinomaSensitivity/ResponseCarboplatin + Paclitaxel + CisplatinCIViC DEID660
KMT2D LossProstate CancerSensitivity/ResponseDoxorubicin + Olaparib + CarboplatinCIViC DEID12806

+4 more predictive associations (showing top 30 by level).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.2
BioBTree
v2.0.2

Sources 17

This page pulls from 17 datasets indexed by BioBTree:

chebichembl_activitychembl_moleculechembl_targetcivic_evidenceclinical_trialsefogtopdb_interactiongtopdb_ligandhgncmeshmondopatent_compoundpharmgkbpharmgkb_guidelinepubchemuniprot